Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.

Autor: Macklin GR; London School of Hygiene and Tropical Medicine, London, United Kingdom; Polio Eradication, World Health Organisation, Geneva, Switzerland., Peak C; Bill and Melinda Gates Foundation, Seattle, Washington, United States., Eisenhawer M; Polio Eradication, World Health Organisation, Geneva, Switzerland., Kurji F; FDK Consulting LLC, Kirkland, Washington, United States., Mach O; Polio Eradication, World Health Organisation, Geneva, Switzerland., Konz J; PATH, Seattle, Washington, United States., Gast C; PATH, Seattle, Washington, United States., Bachtiar NS; Bio Farma, Bandung, Indonesia., Bandyopadhyay AS; Bill and Melinda Gates Foundation, Seattle, Washington, United States. Electronic address: ananda.bandyopadhyay@gatesfoundation.org., Zipursky S; Polio Eradication, World Health Organisation, Geneva, Switzerland.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2023 Apr 06; Vol. 41 Suppl 1, pp. A122-A127. Date of Electronic Publication: 2022 Mar 17.
DOI: 10.1016/j.vaccine.2022.02.050
Abstrakt: To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2), Global Polio Eradication Initiative (GPEI) partners are working closely with countries to deploy an additional innovative tool for outbreak response - novel oral polio vaccine type 2 (nOPV2). The World Health Organization's (WHO) Prequalification program issued an Emergency Use Listing (EUL) recommendation for nOPV2 on 13 November 2020. The WHO's EUL procedure was created to assess and list unlicensed vaccines, therapeutics and diagnostics to enable their use in response to a Public Health Emergency of International Concern (PHEIC). nOPV2 was the first vaccine to receive an EUL, paving the way for other emergency vaccines. In this report, we summarise the pathway for nOPV2 roll-out under EUL.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: